Board Initiates Voluntary Administration
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Paradigm Biopharmaceuticals Ltd. has initiated a voluntary administration process to restructure its balance sheet while reviewing its clinical program and study data. The Board has appointed administrators to assess the company's financial position and explore restructuring options. The company plans to develop a proposal for a deed of company arrangement to manage its liabilities and preserve its intellectual property. The overall clinical review and restructuring process is expected to take at least eight weeks, with the company's securities remaining suspended from trading.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Continuation of Voluntary Suspension
- Agreement to Return US$2M to Obsidian
- Phase 3 Interim Result Below Continuation Threshold
- Suspension from Quotation
- Appendix 4E and 2026 Annual Report
Later from Paradigm Biopharmaceuticals
- Appointment of Voluntary Administrators
- Continuation of Suspension from Quotation
- PPS Shows Significant Pain Benefit in Rest of World Analysis
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals